Article
The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.
Thrombosis and haemostasis - 1 Jul 2004
Visser Loes E, van Schaik Ron H N, van Vliet Martin, Trienekens Paul H, De Smet Peter A G M, Vulto Arnold G, Hofman Albert, van Duijn Cornelia M, Stricker Bruno H Ch
Abstract excerpt
The principal enzyme involved in coumarin metabolism is CYP2C9. Allelic variants of CYP2C9, CYP2C9*2 and CYP2C9*3, code for enzymes with reduced activity. Despite increasing evidence that patients with these genetic variants require lower maintenance doses of anticoagulant therapy, there is lack...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.